Companies facing multibillion-dollar exposure from mass-tort personal-injury litigation have faced massive jury verdicts in 2024. In this Votes and Verdicts episode, BI litigation analyst Holly Froum is joined by mass-tort expert and attorney Joseph Fantini to discuss some of the major litigation facing consumer and industrial companies, including cancer claims against Bayer’s Monsanto weedkiller, Zantac lawsuits against drugmakers GSK and others, NEC litigation against Abbott and Reckitt’s Mead Johnson unit and PFAS cases against 3M and other manufacturers. They discuss potential catalysts, the strength of cases, as well as likelihood of potential global settlements.

See omnystudio.com/listener for privacy information.

What are the major impacts to the markets under an administration of former President Donald Trump or Vice President Kamala Harris? What are the risks and opportunities? SkyBridge Capital Co-Founder and Managing Partner Anthony Scaramucci joined Bloomberg Intelligence analysts Nathan Dean and Elliott Stein to discuss the market, sector and other impacts of the US elections. He also discussed his views on the current status of the SEC and whether US policymakers will develop a new regulatory framework for the cryptocurrency industry.

See omnystudio.com/listener for privacy information.

A key TikTok hearing in its fight against the US government’s “sale or ban” law, Coinbase in court to force the SEC to make crypto rules, and Google fighting DOJ antitrust actions on multiple fronts are catalysts to watch in September. In this episode of the Votes and Verdicts podcast, host and Bloomberg Intelligence senior litigation analyst Elliott Stein gathered colleagues to discuss these and other litigation and policy themes. These include trials in the FTC’s challenges to the Kroger-Albertsons and Tapestry-Capri deals, a securities fraud suit against Bausch Health, a trial against Abbott and Reckitt’s Mead Johnson unit over infant formula products, and Robinhood trying to beat class-certification in a customer lawsuit over best execution disclosures. Also discussed were drug-pricing cuts under the Inflation Reduction Act, the impact of Kamala Harris’ policies on the consumer sector and the possibility of the DEA rescheduling marijuana.

See omnystudio.com/listener for privacy information.